Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected to be Effective Against the Omicron VariantPRNewsWire • 12/07/21
Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in a First-of-its-Kind Preventative Breast Cancer Vaccine StudyPRNewsWire • 10/26/21
Anixa Biosciences Announces First Chinese Patent on its CAR-T Cancer Therapy TechnologyPRNewsWire • 10/06/21
Anixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer TherapyPRNewsWire • 10/01/21
Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at Upcoming Emerging Immunotherapeutics for Ovarian Cancer SymposiumPRNewsWire • 09/14/21
Anixa Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment ConferencePRNewsWire • 09/08/21
Anixa Biosciences and Moffitt Cancer Center Announce FDA Clearance to Initiate Clinical Trial of Ovarian Cancer CAR-T ImmunotherapyPRNewsWire • 08/30/21
Anixa Biosciences' COVID-19 Compounds Show Potential Efficacy Against Delta VariantBenzinga • 08/25/21
Anixa Biosciences' Covid-19 Compounds Expected to be Effective Against the Delta VariantPRNewsWire • 08/25/21
Anixa Biosciences Congratulates Director, Dr. Arnold Baskies for His Appointment to the WHO's Global Breast Cancer InitiativePRNewsWire • 08/23/21
Anixa Biosciences Announces Issuance of U.S. Patent for Ovarian Cancer Vaccine TechnologyPRNewsWire • 08/18/21
Anixa Biosciences Announces Support from the National Cancer Institute for Ovarian Cancer Vaccine Developed by Cleveland ClinicPRNewsWire • 05/26/21
Anixa Biosciences and Moffitt Cancer Center Receive Additional Information Request from US FDA for CAR-T IND ApplicationPRNewsWire • 05/20/21
Anixa Biosciences and Moffitt Cancer Center Report US FDA Request of Additional Information for CAR-T TherapyPRNewsWire • 04/19/21
Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 TherapeuticPRNewsWire • 04/05/21
Anixa Biosciences Increases Previously Announced Bought Deal Offering of Common Stock to $22.5 MillionPRNewsWire • 03/23/21
Anixa Biosciences and Moffitt Cancer Center File IND Application for Ovarian Cancer CAR-T TherapyPRNewsWire • 03/22/21